MedPath

Retrospective analysis of perioperative outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC), based on a surgical database of the University Hospital Dresden, referring to the years 2013-2020

Conditions
C16
C18
C20
C22
Malignant neoplasm of stomach
Malignant neoplasm of colon
Malignant neoplasm of rectum
Malignant neoplasm of liver and intrahepatic bile ducts
Registration Number
DRKS00028850
Lead Sponsor
niversitätsklinikum Carl Gustav Carus
Brief Summary

Introduction It has been shown that cytoreductive surgery (CRS) in combination with hyperthermic intraperitoneal chemotherapy (HIPEC) is an effective treatment for patients suffering from peritoneal malignancies. Despite good results, there is an ongoing debate about this treatment due to perioperative morbidity. The aim of this study is to identify relevant risk factors for an unfavorable postoperative outcome after CRS and HIPEC. Materials and methods A retrospective analysis of a prospectively recorded database of all patients undergoing CRS and HIPEC between 2013 and 2020 in the Department of Surgery of the University Hospital Dresden was performed with a special focus on certain surgical steps of multivisceral resection, one- or 2- stage CRS/HIPEC and underlying diagnosis as possible risk factors for worse postoperative course. Results N = 173 CRS and HIPEC procedures were performed for various diagnoses. Relevant postoperative morbidity was 24% and 30d-mortality 1.2%. Simultaneous liver resections, preoperative hypalbuminemia and 2-staged CRS/HIPEC were significant risk factors for a worse postoperative course in multivariable analysis. Assessment of the association of simultaneous anastomoses and morbidity and mortality was inconclusive. Conclusion CRS and HIPEC is a safe treatment without relevant intraoperative morbidity and mortality and acceptable postoperative outcome. One-stage CRS/HIPEC should be preferred.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
173
Inclusion Criteria

All patients who received cytoreductive surgery and/or HIPEC (regardless of underlying diagnosis) in the UKD (VTG) from 2013-2020 will be included.

Exclusion Criteria

does not apply

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Analysis and presentation of patient characteristics, perioperative and postoperative parameters, and oncological parameters.
Secondary Outcome Measures
NameTimeMethod
-Univariate and multivariate analysis for the identification of risk factors for the occurrence of postoperative morbidity and mortality. <br>- Subgroup analyses with respect to the underlying tumor Tumor disease as well as the HIPEC regimen used.
© Copyright 2025. All Rights Reserved by MedPath